Leading the Way in Life Science Technologies

GEN Exclusives

More »

Wall Street BioBeat

More »
Nov 1, 2010 (Vol. 30, No. 19)

Biotech Posts Strong Third-Quarter Results

Robust Performance Hailed as Strongest September Rally in More than 70 Years

  • IP Queue

    In addition to these two biofuel companies, several other biotechs filed to add themselves to the IPO queue in the quarter including:

    • Complete Genomics (www.completegenomics.com), has already sequenced more than 200 complete human genomes since the beginning of the year, according to its filing.
    • Horizon Pharma (www.horizonpharma.com), has a product on the market in Europe. Lodotra is a low-dose formulation of prednisone, for the treatment of rheumatoid arthritis.
    • Aegerion Pharmaceuticals (www.aegerion.com) is focused on the development and commercialization of pharmaceuticals to treat cardiovascular and metabolic diseases.
    • Cutanea Life Sciences (www.cutanealife.com) is a development-stage specialty pharmaceutical company whose mission is to strategically in-license novel, mid-stage candidates to treat diseased and aging skin conditions.
    • Endocyte (www.endocyte.com) is developing targeted therapies for the treatment of cancer and other serious diseases.
    • Pacific Biosciences (www.pacificbiosciences.com) has developed a single molecule, real-time technology that enables analysis of biomolecules with single-molecule resolution.
  • Public Company Financings Soft

    Analysis in the Burrill Report shows that, apart from debt financings, all other financing vehicles were down a collective 50%, compared with the second quarter of 2010.

    Follow-on financing and IPOs were down quarter-over-quarter; however, padding the data was the $7.2 billion raised in debt financing, bringing the total raised in the third quarter to $9.5 billion.

    Venture capital financing continued to flow to U.S. biotech companies with $1.3 billion raised from about 90 deals announced in the third quarter. The U.S. biotech industry is on track to raise over $20 billion by the end of the year.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »